Corcept Therapeutics to Announce Fourth Quarter and Full Year Revenue and Corporate Update and Host Conference Call
January 27 2014 - 08:30AM
Marketwired
Corcept Therapeutics to Announce Fourth Quarter and Full Year
Revenue and Corporate Update and Host Conference Call
MENLO PARK, CA--(Marketwired - Jan 27, 2014) - Corcept
Therapeutics Incorporated (NASDAQ: CORT) today announced it will
report fourth quarter and full year 2013 revenue on January 30,
2014. The Company will also host a conference call that day at 5:00
p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
To participate, dial 1-888-771-4371 from the United States or
1-847-585-4405 internationally approximately 10 minutes before the
start of the call. The passcode is 36540064.
A replay will be available through February 13, 2014 at
1-888-843-7419 from the United States and +1-630-652-3042
internationally. The passcode is 3654 0064.
About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery,
development and commercialization of drugs for the treatment of
severe metabolic, psychiatric and oncologic disorders. Korlym, a
first generation GR antagonist, is the company's first FDA-approved
medication for use in the treatment of patients with Cushing's
syndrome. Corcept has a phase 3 trial underway for mifepristone for
treatment of the psychotic features of psychotic depression, as
well as a portfolio of selective GR antagonists that block the
effects of cortisol without blocking the effects of progesterone.
It owns extensive intellectual property covering the use of GR
antagonists, including mifepristone, in the treatment of a wide
variety of disorders. It also holds composition of matter patents
for its selective GR antagonists. For more information about
Corcept please visit: www.corcept.com
CONTACT: Charles Robb Chief Financial Officer Corcept
Therapeutics 650-688-8783 Email Contact www.corcept.com
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Mar 2023 to Mar 2024